Get the Stockscreener App
0.845
6.83%
0.054
After Hours:
.85
0.005
+0.59%
Galmed Pharmaceuticals Ltd stock is traded at $0.845, with a volume of 160.98K.
It is up +6.83% in the last 24 hours and down -2.32% over the past month.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.
See More
Previous Close:
$0.791
Open:
$0.8
24h Volume:
160.98K
Relative Volume:
0.08
Market Cap:
$4.63M
Revenue:
-
Net Income/Loss:
$-8.72M
P/E Ratio:
-0.154
EPS:
-5.4871
Net Cash Flow:
$-5.47M
1W Performance:
+5.49%
1M Performance:
-2.32%
6M Performance:
-57.54%
1Y Performance:
-70.45%
1-Day Range:
$0.7922
$0.8721
1-Week Range:
$0.7902
$0.8721
52-Week Range:
$0.7311
$3.50
Galmed Pharmaceuticals Ltd Stock (GLMD) Company Profile
Name
Galmed Pharmaceuticals Ltd
Sector
Industry
Phone
-
Address
-
Compare GLMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GLMD
Galmed Pharmaceuticals Ltd
|
0.845 | 4.33M | 0 | -8.72M | -5.47M | -5.4871 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Galmed Pharmaceuticals Ltd Stock (GLMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-22-20 | Downgrade | B. Riley FBR | Buy → Neutral |
| Feb-04-20 | Initiated | Craig Hallum | Buy |
| Jan-30-20 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-02-19 | Initiated | Canaccord Genuity | Buy |
| Dec-12-18 | Initiated | B. Riley FBR | Buy |
| Aug-02-18 | Reiterated | Maxim Group | Buy |
| Jul-13-18 | Initiated | Stifel | Buy |
| Jul-12-18 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-12-18 | Reiterated | H.C. Wainwright | Buy |
| Mar-15-18 | Upgrade | Maxim Group | Hold → Buy |
| Feb-14-18 | Downgrade | Maxim Group | Buy → Hold |
| Feb-12-18 | Reiterated | H.C. Wainwright | Buy |
| Nov-15-17 | Initiated | ROTH Capital | Buy |
| Aug-08-17 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-17 | Reiterated | Maxim Group | Buy |
| Aug-01-16 | Reiterated | Maxim Group | Buy |
| Jul-06-16 | Resumed | ROTH Capital | Buy |
| Mar-28-16 | Resumed | H.C. Wainwright | Buy |
| Jun-23-15 | Initiated | H.C. Wainwright | Buy |
| May-06-15 | Initiated | Sun Trust Rbsn Humphrey | Buy |
View All
Galmed Pharmaceuticals Ltd Stock (GLMD) Latest News
Published on: 2026-01-20 07:51:30 - bollywoodhelpline.com
Market Review: Can Home Bancorp Inc maintain its current growth rateQuarterly Portfolio Summary & Consistent Profit Alerts - baoquankhu1.vn
How volatile is Galmed Pharmaceuticals Ltd stockTrade Analysis Summary & Scalable Portfolio Growth Methods - baoquankhu1.vn
Price Action: What are IBKRs technical support levelsQuarterly Trade Report & Short-Term High Return Strategies - baoquankhu1.vn
Galmed Pharmaceuticals (NASDAQ:GLMD) Share Price Crosses Below 50-Day Moving Average – Should You Sell? - Defense World
Trade Recap: Is Galmed Pharmaceuticals Ltd stock a good dividend stock2025 Analyst Calls & Long-Term Growth Stock Strategies - baoquankhu1.vn
Chart Watch: Will Galmed Pharmaceuticals Ltd benefit from government policyWeekly Investment Report & Smart Investment Allocation Insights - baoquankhu1.vn
Stock Report: Is Galmed Pharmaceuticals Ltd in a long term uptrendJuly 2025 Market Mood & Daily Growth Stock Tips - baoquankhu1.vn
Galmed Pharmaceuticals Secures Shareholder Approval at Annual Meeting - MSN
Volume Report: How Galmed Pharmaceuticals Ltd GPH stock expands through international marketsPortfolio Value Report & Free Verified High Yield Trade Plans - Bộ Nội Vụ
Will Galmed Pharmaceuticals Ltd. stock outperform Dow Jones indexPortfolio Value Report & Verified Short-Term Plans - ulpravda.ru
What makes Galmed Pharmaceuticals Ltd. (GPH) stock appealing to growth investorsMarket Risk Analysis & Fast Exit and Entry Trade Guides - Улправда
What technical charts say about Galmed Pharmaceuticals Ltd. stockMarket Performance Summary & Stepwise Entry and Exit Trade Signals - ulpravda.ru
How Galmed Pharmaceuticals Ltd. stock reacts to job market data2025 Performance Recap & Low Drawdown Momentum Ideas - Улправда
Can Galmed Pharmaceuticals Ltd. stock surprise with earnings upsideJuly 2025 Big Picture & Advanced Swing Trade Entry Alerts - Улправда
How Galmed Pharmaceuticals Ltd. (GPH) stock expands through international marketsJuly 2025 Review & Free Technical Confirmation Trade Alerts - Улправда
Is Galmed Pharmaceuticals Ltd. (GPH) stock worth buying before Fed actionJuly 2025 Drop Watch & Smart Investment Allocation Insights - Улправда
Published on: 2026-01-09 00:35:39 - ulpravda.ru
Galmed Pharmaceuticals Ltd.Ordinary Shares (NQ: GLMD - FinancialContent
GLMD Stock Price, Forecast & Analysis | GALMED PHARMACEUTICALS LTD (NASDAQ:GLMD) - Chartmill
What drives Galmed Pharmaceuticals Ltd GPH stock priceTrade Execution Strategies & Small Capital Investment Tips - Early Times
EBIT per share of Galmed Pharmaceuticals Ltd. – BER:GPH - TradingView — Track All Markets
Will Galmed Pharmaceuticals Ltd. stock outperform tech sector in 2025Market Sentiment Surveys & Free Rapid Wealth Multiplication - bollywoodhelpline.com
Is Galmed Pharmaceuticals Ltd. stock a defensive play in 2025Evening Star Patterns & High Profit Market Ideas - bollywoodhelpline.com
Downgrade Watch: Why Galmed Pharmaceuticals Ltd stock is seen as undervalued2025 Short Interest & Weekly Breakout Stock Alerts - Bộ Nội Vụ
Financial Survey: Galmed Pharmaceuticals (NASDAQ:GLMD) vs. Qualigen Therapeutics (NASDAQ:QLGN) - Defense World
Will Galmed Pharmaceuticals Ltd. stock benefit from upcoming earnings reportsJuly 2025 Review & Low Drawdown Investment Strategies - Улправда
Aug Selloffs: How interest rate cuts could boost Galmed Pharmaceuticals Ltd. stock2025 Key Lessons & Long-Term Growth Portfolio Plans - Улправда
How interest rate cuts could boost Galmed Pharmaceuticals Ltd. stock2025 Price Action Summary & Daily Stock Trend Watchlist - Улправда
Galmed Pharmaceuticals (NASDAQ:GLMD) Share Price Passes Below Two Hundred Day Moving Average – Here’s What Happened - Defense World
How big funds are accumulating Galmed Pharmaceuticals Ltd. (GPH) stockMarket Capitalization Trends & Outperform the Market with Aggressive Picks - Bollywood Helpline
Is Galmed Pharmaceuticals Ltd. (GPH) stock a safe buy pre earningsMarket Trend Review & Weekly Top Gainers Trade List - DonanımHaber
Galmed to present data on Aramchol’s potential in liver cancer By Investing.com - Investing.com Canada
Galmed to present data on Aramchol’s potential in liver cancer - Investing.com
Galmed Pharmaceuticals’ Aramchol Abstract Accepted for HEP-DART 2025 Presentation - TipRanks
Galmed Pharmaceuticals’ Aramchol abstract accepted for HEP-DART 2025 presentation - MSN
Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting - PR Newswire
Galmed receives patent for combination therapy in South Korea By Investing.com - Investing.com Nigeria
Can Galmed Pharmaceuticals Ltd. (GPH) stock surprise with quarterly resultsBuy Signal & Weekly Breakout Watchlists - Newser
Galmed Announces Grant of New Use Patents for the Combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra for Mash - marketscreener.com
Galmed stock rises after patent grant for MASH combo therapy By Investing.com - Investing.com Nigeria
Galmed Pharmaceuticals Ltd Stock (GLMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.09%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):